medical_t_179

ISSN 1106-3157

EKOTN

(X

+7) EHM

EPIE EPIOIK

A

. KEMA

385/1989

ME

DIC

AL

EX

PR

ES

S

17

9

20

09

. ... 102166 74 e-mail: [email protected]

12956=$'

> .

> . www.bravogiorgo.gr

> . ... !

> . ... !

> !

18 / 179 / 2009

MedicalExpress

-

... ...

EXOFILO 179.qxl 10/23/09 3:12 PM Page 1

TEYXOS 179.qxl 10/23/09 3:04 PM Page 3

. . .

Und

erth

elic

ense

ofDAIIC

HI S

ANKYO

SEVI-M

A01-A

pril2009

PFIZER HELLAS A.E.

243 - 154 51 . .: 210 6785800 210 8199060

NEO


8 / MEDICAL EXPRESS / TEYXO 179 / 2009

36

24OO

.. ....,, .. 110022,,1166667744 ,, ..:: 221100--8899..4477..000022,,

FFaaxx:: 221100--8899..4411..555511,, wwwwww..ppiittssiilliiddiiss..ggrr,, ee--mmaaiill:: iinnffoo@@ppiittssiilliiddiiss..ggrr

:: 11998855

OO MM ,,

.. 1111,, BB 116666 7733

NN

IIEEYYYY

OOHH IIEEYYYY

OOOONNOOMM

AARRTT DDIIRREECCTTOORR

,,

,,

:: CCooppyyrriigghhtt MMeeddiiccaarrtt SSAA

.. ....

MedicalExpress

10

EDITORIAL

www.bravogiorgo.gr 12

... ! 14

16

&

... ! 20

! 24

H

AA AA--YY 30

36

, 42

46

48

... ... 80



, - , -

. - - - - - - - - , 1891. Lesmorticoles ( - ), , - . , , ., . ; - ; , ; ; ! - !. : ; ! !.

, ,, - - 19 20 . - , , -

. - , -, -. , , - -. , -

, .

, , - . , - - . - , , . - -: ; - ; ;. -

. : , , - . - - - . - . - , .

, - . - - - . , - , Francoisde La Rochefoucauld, 15 . - -.

.. ,,



E D I T O R I A L

www.bravogiorgo.gr

- -, 88

; , -; ; ; - - , , ; . , , , - , .

-. - , , , , . - - - . ; , - , -, , - - -, - , , - . , , ! ! - , - - -

, - , , - .. - , - ,

-. , - , - - . , , , -, , - - .

, - , - ( - ) - -. .. ; - -; - - ; - ; - , - - ,

- - -. , 7-8 , ( 1) -!!! , - , - . - , - - , ( ) - . ; , , - !!! , ,

ppiittssiilliiddiiss@@ggmmaaiill..ccoomm

, ! !


~sn|ss~s}y|}jon &,35$/(;PJ&,35$/(;PJ&,35$/(;PJPOj||}{}s|jn|}{ngyn{ &LSUDOH[PJ}PJHVFLWDORSUDP&LSUDOH[PJ}PJHVFLWDORSUDP&,35$/(;PJPO}POPJHVFLWDORSUDP PJHVFLWDORSUDPR[DODWH}PJHVFLWDORSUDPsyfy|iy|nHVFLWDORSUDP~s|f|s|yynjy|fj|{ny|n}s|jhsiy|n}ss{{n{ 665,V &LSUDOH[y j ~sny}j665,V665,V~ 665,V{665,Vfn665,y sn{f s{665,V615,V sn 6,$'+665,V{j$665,Vs665,V 16$,'V {(&7665,V(&7s ~ssHVFLWDORSUDP~sse~snnnHVFLWDORSUDP6W-RKQV:RUW+\SHULFXP3HUIRUDWXPx{ 6W-RKQV:RUW+\SHULFXP3HUIRUDWXPx665,Vn e eHVFLWDORSUDP nn syj|g~{ynyyey|yn f~fny$'+fn nOLELGResn~~f nsfnnn~f~fy}nxs~fsg~n ejnfef~{fn }~yfnsf~}fn e~en}ns~~j665,V}47fn{ 665,V65,Vz }snsfy|sn}}h|sn +/XQGEHFN$62WWLOLDYHM'.&RSHQKDJHQ9DOE\'HQPDUNj/XQGEHFN+HOODV6$}~s)D[


- . ,

, , -, , ...

( - ) - , -, , - - . , -, Mont Blanc, - ...

- - ( ) - , , , , - , - !

- ..., .

- , - , -

, - . - , : . - - . , ...!

, - - .

, (210/2-10-09 ) (- !) , - , . , , 51% - . -

, .. - - , . , .

... ,, , .. , - , - - -, !

, - , -, , . -, , ., , - .

.. , , , .

, - - .... - , ,... ... -, ... !

E

... !

tt..ppaappaavvaassiilliioouu@@ppiittssiilliiddiiss..ggrr



&

; - , - - , , . - - (- ) , - , - - . , -

-, - , . - , - .

, -, - , , , , - . , - ( ) , , , , - - .

- ( ) , - , - , , . - - , - , - , , , , , ...

- , ,

, , - , -, . , -, - - 16 , , - - , . : - . , - , - .

, . , , , ,, , - - . - , .

... all time classic!



&

... , - , , , , - , - . - - . - (National Clinical AssessmentService - NCAS), - , , 837 - ( 20% ), 3.635 . , : , - 50 - , 290 . , - , - NCAS, . - : , - - . , - - , - .

, - -. - , . - 57% - , - . - . -

-, , , - . - - . , . - , - , - , .

-. - - barcode , . , , .

, , - . - -

- . - - , , - -. , - - -. - , - .



- , - (Euro

Health Consumer Index), - 33 ( 27 EE, , , , FYROM, ). 19 (), 23, ... - 600 1.000.

- ( 599 ), - , - - , - - . - , - -, , FYROM.

- 38 , ( -, ): , - , - , ( -, -, ), -

.

, ( ),, . , - , - (e-health) , - - (.. ). , , , . , , -

&

0 200 400 600 800 1000

FYROM

875819

811795788787

778762760

740732

721701

682671668667

638637633630627

600576574

565565560

546542

512489

448

. - : . : , . -: , , ,. : -. -: , ,. -: ,


(.. , - ).

, HealthConsumer Powerhouse - - . . . - , - . - , -, . -, , , management. management - 2001 2004, -, - , - & - , . - : - , .

, - , , . , -

2009 / TEYXO 179 / MEDICAL EXPRESS / 21

23 ...

... !

T , ESQH Executive Board Member, (....)

Health Consumer Powerhouse, - , . ,

, , . , , ... : - - - .

- , . , - , : (patient safety) (patient centeredness).

, , , , . , , - , : - .

, (patient safety) - (patient centeredness) . , , (patientsafety) - (patient centeredness) : , - - .

, (e-health), . , , , , - , , , . , , , , -, , (e-health) ; , - - , , !



. , 100.000 ( 530 - 410 ), - , - - , - , , 2005 5 - . Health ConsumerPowerhouse, - - - 2005- , - .

- , , - , Arne Bjornberg, - -: - .

, , , , -, . - , , . -, , management , (generics), 80% .

, - , - 1 2 , ... - , , - 31 . - , , , 787 .

user-friendly - ... -

, , , , -, , , - .

, - , - , - . - , ,

, .. - - - , - . . , - , -, , , - -- , - .

T , , , 7 ( ), - - , 7 . , , , 2008 , 2006, , 7 .

, , - -, - . . , , , - , .

- - , , . - , 33 - .

&

. : 84/175. -: 25/75. :147/200. - : 190/250. :79/150. -: 75/150

TEYXOS 179.qxl 10/26/09 11:46 AM Page 22

Revatio (sildenafil, ). 20mg. E: , , . . : . / (cGMP), sildenafil ( ) . CYP3A4 (.. , , ). T Revatio - (), PDE5. sildenafil : , , ( < 90/50mmHg) . : Revatio ( V). , , (.. epoprostenol). / sildenafil . . sildenafil : , ( ), . , - . 20mg , CYP3A4 . 20mg , CYP3A4, , . H CYP3A4 (.. , , ) sildenafil . sildenafil CYP3A4. sildenafil, sildenafil, , , . silde-nafil , Revatio . sildenafil , , sildenafil, : , , , , , , . , , . silde-nafil, . .o sildenafil, ( , Pey-ronie) ( , ). - sildenafil PDE5. , Revatio . sildenafil -, . , - sildenafil. . sildenafil in vitro. , sildenafil . , sildenafil . , sildenafil , . sildenafil . , ( ) . , sildenafil , . . , Lapp -, . : , Revatio , 207 Revatio , 20mg 80mg, 70 . 12 . 259 , . 80mg (4 20mg ), (=149 1 , 101 80mg ). sildenafil, 20mg (2,9%), (2,9%). , , Revatio epoprostenol, , 134

Revatio ( 20mg 40mg 80mg, ) epoprostenol, 131 epoprostenol . 16 . , , sildenafil/epoprostenol, 5,2%, 10,7% /epoprostenol. , , sildenafil/epoprostenol, / , , , , . , , , sildenafil/epoprostenol /epoprostenol. . , Revatio( 10%) , , , , . sildenafil , 20mg (2,9%) (2,9%). O , > 1 % Revatio ( > 1%) Reva-tio Revatio 20, 40 80 mg , ( (> 1/10), (> 1/100, < 1/10), ( 1/1000, < 1/100) ( )). , . . MedDRA , , () ,

, , , , , , ,

, , , , ,

*

, , , , , ,

, , , , ,

, ,

,

, * 5, sildenafil. sildenafil , : : (), , . :Pfizer Limited, Sandwich, Kent CT13 9NJ, . : PFIZER HELLAS A.E., 243, 154 51, . , . 210 6785800. : EU/1/05/318/001. : 07/07/2009 . : Revatio f.c. tab 90 x 20mg,..: 690,52 . . , , . .

() REVATIO, 5 60.000 1, () II , III.

PFIZER HELLAS A.E.. 243, 15451 . , .: 210 6785800, Fax.: 210 6785971

1. IMS worldwide sales volume, Q2 2005 to Q1 2009.

N

II

REVA-MA01-September 2009



ESH - (ESH), , - - . , Recordati - : , - -: . - Serap Erdine ( - - ) Giuseppe

Mancia ( ).

5 ArrigoRecordati 2009, - - . . Recordati, .Giovanni Recordati, , . Robert O. Bonow, - 2009, . Valentin Fuster, Mount SinaiHeart, , -

, .

, - (), - -- .

- (ESH) (ESC) 2007 , - , - . - , -

.... !

14 , -, . 100 , 17,5 . , , . , . , , , . : (. .42000/14734/532- 1460//24-7-08), - , (. ) 2006 3.218.312.756,71 2007 3.831.824.232,45 . - , . , , , 14 - , -, 5 . , - .

. , - , , , - , 30% .

- , , , , , , - .



, , - - - . , - - . . -, , - - : - , -

. ASCOT ACCOMPLISH, - , - -, - . , , , , . , ., -

, - -, - . : , - - . - , ,

, - -. , - , - - . , - ., - .

, , - .

.. , 9 20 . , , - 1 & 2, -, , . , - , - , 4 ... -. - , -, -, . , . , - -, , , -, , ,, , ,.., , , -, , , -, , , -, , , , - ( ). -, (, ), - , .

- 25 , -


24

1-4

&

Boehringer Ingelheim E A.E. A: E 2, 167 77 E, T.: 210 89 06 300, : 15-17 & 6, 57001, , . 2310 424618

DC00

0425

MIC

MIC

PLUS

2/0

9

.

..

.1. Lacourcire Y., et al. Blood Press Monit. 1998;3:295-302. 2. Smith D.H.G., et al. Blood Press Monit. 2003;8:111-117. 3. White W.B., Lacourcire Y., Davidai G. Am J Hypertens. 2004;17:347-353. 4. The ONTARGET Investigators. New Engl J Med. 2008;358:1547-1559 .



, 14 . - , - , - , , -, , 7 - / . GALENICA, - .

- , - - Da Vinci S. - - --

Stanford (). , / - , -- . . , - 2 24.

4 . 75% .

. . , - - , , - - / , - .

- - , . -, , - , , - , (- ). , - .

- - - : , , - () - , 24, - .

Greece Race for the Cure

Novartis, 27 2009, - Greece Race for the Cure, , Susan G. Komen for the Cure. , , , - , Novartis. Novartis , , , - . ,

, . - . , 4.500 , 68 . Susan G. Komen Race for the Cure Series

5., 26 -

, . Nancy Brinker, Susan G. Komen for the Cure, 26 , , , . 800 , Race for the Cure - 1,5 100.000 . 2009 130 , - , , & , , , , , -, , , , , .


PFIZER HELLAS A.E.. 243, 15451 . , .: 210 6785800, Fax.: 210 6785971

NEUR

-MA0

1-Se

ptem

ber2

009

, ..., Pfizer Hellas A.E.



:

-- -

1960. , , , - - . , - - - . , , - , , , - . , - , -, . , - , - .

, 1983 - .

,

- , - . . . , - - -, --, , 11.048 -, -, ! - , , , -

, - . , , - . , 1000 , 24 , , .

, .

, - - - , . - - , - , . , (, , ), - . - - ( , , , ..). -

A A-YH H I

---- -- ,, .. -- ,, -- ,, -- -- .. -- ,,MMaasstteerr ooff SScciieennccee iinn MMootthheerraanndd CChhiilldd HHeeaalltthh -- -- ..


, , - . - , - , , - , , - - .

, , .

15 -, - , - - . , - (), - , , .

2 , , -, - , , 1 30 1998. - - 24% 1983 10,5% 1998, 56%!.

, - .

. -, , -

, -, - - , . , - , .

, , - - - - - , .

25%, - 2500 !.

, 32% - , 9-13%; - , 1 3 - , - 20%. , 2 1998. . -

, , , 15 .

, - - 60%, - . - - . , - 35 45. -. - , , - . , , - , - .

- - , - ( ), - . , - . - -, - . - - - .

. . , , - - . ,


- - ,


@B

DC

000

416

MES

01/

09

'TJMWNSLJW.SLJQMJNR*+F]


- , - - , , - , ,

- . - .

; - -. - - , . -, -, - .

; -, - .

, - , - , - , -. - , , - - - ,

- . , - - - , - , , - .

-- . , - -

., - , -, -, .

- ; , . , , - . - ,

- , . - , - - -, - -, - . , , , - .

.

, - -, - , - - , , -, , , . - - , , , -, , - .

; -, , - - , -- - - - . , , -, , , .

34 / MEDICAL EXPRESS / TEYXO 179 / NOEMB 2009

- - -



. ,

, , , -

- . , , - , - , -, .

, , - - , - . , - , - , , - , ( - ).

(, , , - ). . , , , , - - . -, -

. , - - ., , - , - .

, - - , - - ., , - - . , - , , - , - . -, , .

, , , - - . , -

, , - , ., - , - . - , C-- (CRP) -, .

, - - . - - . -, - - . - Porphyromonas gingivalis, Tannerellaforsythensis, Prevotella intermedia -, - - .

, - - , C- - (CRP), , , , - (TNF-) , -, - -



.,

- . 1980, - - ., - (NHANES III) , - - , . -, - - 1,3 2 - . , - .

, - C- (CRP) - , , .

, , - , - - , - . - - , - .

, - , -, , -, , , ., - -

, -, -, 1993 - 6 - . , , - , - . - -, - -

., , .

, , - - , , - .

,

, , . - .

, - - - . , , - - , , , . , - - , - .

- , . , - ., , , .

, - - , , - - , -, - - - .

- - , - , - , - .


(

)



, . - , - , - ( - ). - - -, , - . - ( ) - , - - . , - .

1. Desvarieux M, Demmer RT, RundekT, Boden-Albala B, Jacobs DR, Jr., SaccoRL, et al. Periodontal microbiota andcarotid intima-media thickness: Theoral infections and vascular diseaseepidemiology study (INVEST). Circulation2005, 111(5):576-582.2. Ross R. Atherosclerosis Aninflammatory disease. N Engl J Med1999, 340(2):115-126.3. Chun YH, Chun KR, Olguin D, et al.Biological foundation for periodontitisas a potential risk factor for atherosclerosis.J Periodontal Res. 2005, 40:87-95.4. Haraszthy VI, Zambon JJ, TrevisanM, Zeid M, Genco RJ. Identificationof periodontal pathogens in atheromatousplaques. J Periodontol 2000, 71(10):1554-1560.

5. Desphande RG, Kahn MB, GencoCA. Invasion of aortic and heart endothelialcells by Porphyromonas gingivalis.Infect Immun 1998, 66:5337-5343.6. Herzberg MC, Meyer MW. Effects oforal flora on platelets: Possible consequencesin cardiovascular disease. J Periodontol1996, 67(10 Suppl):1138-1142.7. Meurman JH, Sanz M, Janket SJ.Oral health, atherosclerosis, andcardiovascular disease. Crit Rev OralBiol Med 2004, 15(6):403-413.8. Scannapieco FA. Periodontalinflammation: From gingivitis to systemicdisease? Compend Cont Educ Dent2004, 25(7 Suppl 1):16-25.9. Genco R, Offenbacher S, Beck J, ReesT. Cardiovascular diseases and oralinfections. In: Rose LF, Genco R, CohenDW, Mealey BL, eds. Periodontal Medicine.BC Decker Inc.; 2000. pp. 63-82.10. Mattila KJ, Nieminen MS, ValtonenVV, Rasi VP, Kesaniemi YA, Syrjala SL,et al. Association between dental healthand acute myocardial infarction. BMJ1989, 298(6676):779-781.11. DeStefano F, Anda RF, Kahn HS,Williamson DF, Russell CM. Dentaldisease and risk of coronary heartdisease and mortality. BMJ 1993,306(6879):688-691.12. Scannapieco FA, Bush RB, Paju S.Associations between periodontaldisease and risk for atherosclerosis,cardiovascular disease, and stroke. Asystematic review. Ann Periodontol2003, 8(1):38-53.13. Beck J, Garcia R, Heiss G, et al. Periodontaldisease and cardiovascular disease. JPeriodontol. 1996, 67:1123-1137.14. Wu T, Trevisan M, Genco RJ, et al.Periodontal disease and risk ofcerebrovascular disease: the first nationalhealth and nutrition examination surveyand its follow-up study. Arch InternMed. 2000,160:2749-2755.15. Joshipura KJ, Hung HC, Rimm EB,et al. Periodontal disease, tooth loss,and incidence of ischemic stroke. Stroke.2003, 34:47-52.16. Ajwani S, Mattila KJ, Narhi TO, et

al. Oral health status, c-reactive proteinand mortalitya 10 year follow-upstudy. Gerodontology. 2003, 20:32-40.17. Jin LJ, Chiu GK, Corbet EF. Areperiodontal diseases risk factors forcertain systemic disordersWhatmatters to medical practitioners? HongKong Med J 2003, 9(1):31-37.18. Offenbacher S, Katz V, Fertik G,Collins J, Boyd D, Maynor G, McKaigR, Beck J. Periodontal infection as apossible risk factor for preterm lowbirth weight. J Periodontol. 1996, 67(10Suppl):1103-13.19. Offenbacher S, Lieff S, BoggessKA, Murtha AP, Madianos PN, ChampagneCM, McKaig RG, Jared HL, MaurielloSM, Auten RL Jr, Herbert WN, BeckJD. Maternal periodontitis and prematurity.Part I: Obstetric outcome of prematurityand growth restriction. Ann Periodontol.2001, 6(1):164-74.20. Xiong X, Buekens P, Fraser WD,Beck J, Offenbacher S. Periodontaldisease and adverse pregnancy outcomes:a systematic review. BJOG. 2006,113(2):135-43. Review.21. Grossi S.G. Treatment of periodontaldisease and control of diabetes: anassessment of the evidence and needfor future research. Annals of Periodontology2001, 6(1):138-45. Review.22. Kidambi S & Patel BS: Diabetesmellitus. Considerations for dentistry.JADA 2008, 139(10 suppl):8S-18S.23. Lamster IB, Lalla E, Borgnakke WS,Taylor GW: The relationship betweenoral health and diabetes mellitus. JADA2008, 139(10 suppl):19S-24S.24. Mealey BL, Oates TW, AmericanAcademy of Periodontology: Diabetesmellitus and periodontal diseases. JPeriodontol 2006, 77(8):1289-303.25. Mealey BL & Roseb FL: Diabetesmellitus and inflammatory periodontaldiseases. Current Opinion in Endocrinology,Diabetes & Obesity 2008, 15:135141.26. Taylor GW: Bidirectional interrelationshipsbetween diabetes and periodontaldiseases: an epidemiologic perspective.Ann Periodontol. 2001, 6(1):99-112.


6 225.000

, Colgate

. 2002

225.000 .

Colgate

.

Bright Smiles Bright Futures.

500.000.000

17 80 .

Bright Smiles Bright Futures!

.

... B !

500.000.000 80 17

!



, :

() - -

- ().

- , 62% - .

- () , - , - - .

, - - -, . , - INR (international normalizedratio) 1.5, -.

- (-

, - ) -, , - .

-

(OAC) - KM, () . - - , ,

. -, - - , - , - , - .

- MEDLINE, EMBASE, Cochrane - - OAC, 2005, 10 , - 4180 , , o - - .

- , , - - - OAC OAC (OR=0.66). -, - (OR=0.27), -

- - - .



- OAC (OR=0.69).

, , - , OAC (OR=1.43).

- - - OAC, - , - .

, - SPORTIF III IV ( OAC ) , - OAC , , - . , - 1.6% , .

- - .

- , , OAC -, - , , - . -

, , - - , - .

, - NASPEAF -, , , 1209 - , 60 , 2 : : - - - - .

, , 247 -, INR 2-3 223 Aflen 600 mg INR 1,4-2,4. : - -. , 235 (Aflen 600mg), 232 INR 2-3 222 - Aflen600 mg INR 1,25-2.

, 6 , - 3 mg/dl, - , , - - / .

2.76 - - , - , .

, - -, ( [HR] 0.33[ 95%(CI) 0.12 0.91], p=0.02) (HR 0.51[95% CI 0.27 0.96], p= 0.03). - , . - - - .

, - , ,

(), , . , , , , .



- - , , - . -.

(Aflen) - - - - . - - - - , - .

- - . . - - -. - : - - - ., , , COX-1 - 2 , -, - 5AMP cAMP. cAMP .

- . - - - . - - 2, 10 , . (NO) -. .

, - - .

1. Francesco Dentali, James D. Douketis,Wendy Lim, Mark Crowther. CombinedAspirin-Oral Anticoagulant TherapyCompared With Oral AnticoagulantTherapy Alone Among Patients at Riskfor Cardiovascular Disease. A Meta-analysis of Randomized Trials. ArchIntern Med. 2007; 167: 117-124.2. Flaker GC, Gruber M, Connolly SJ,Goldman S, Chaparro S, Vahanian A,Halinen MO, Horrow J, Halperin JL;SPORTIF Investigators. Risks andbenefits of combining aspirin withanticoagulant therapy in patients withatrial fibrillation: an exploratory analysisof stroke prevention using an oralthrombin inhibitor in atrial fibrillation(SPORTIF) trials. Am Heart J. 2006;152: 967-73. 3. Francisco Prez-Gmez, EduardoAlegra, Jesus Berjn, Jose A. Iriarte,Javier Zumalde, Antonio Salvador,Luis Mataix, for the NASPEAFInvestigators. Comparative Effects ofAntiplatelet, Anticoagulant, or CombinedTherapy in Patients With Valvular andNonvalvular Atrial Fibri l lation. ARandomized Multicenter Study. JACC2004; 44: 1557-66

(Aflen) - - .



2g single dose

M. Lucchi, B. Damle, A. Fang, P. J. deCaprariis, A. Mussi, S. P. Sanchez, G. Pasqualetti and M. Del Tacca

: - - -. ER - 2 g, , , - . , [epithelial liningfluid (ELF)], [alveolar macrophages (AMs)] - - ER IR. : 64 - , . - 2 g -ER(32 ) 500 mg-IR (32 ). -, - - - .: --IR, AUC024 , ELF, AMs 3,1, 2,3, 1674 mg.h/L 130mg.h/kg, . -ER AUC024 , ELF, AMs

10,0, 17,6, 7028 mg.h/L 505mg.h/kg . AUC024 -ER -IR 3,2,7,7, 4,2 3,9 , ELF, AMs .: 24, 2 g --ER , - 500 mg --IR, ELF, AMs . - .

, - , -ER - - -IR. -ER: -

(azithromycinExtended Release). Zithromax 2g, .

-IR: - (azithromycinImmediate Release). 500mg

Journal of Antimicrobial Chemotherapy(2008) 61. 884-891.

-- ZZiitthhrroommaaxx 22gg (( 550000mmgg)).. 2244 ZZiitthhrroommaaxx 22gg 550000mmgg,, 2244 .. MM.. LLuucccchhii eett aall..


ZITH

PED-0

08-0

8

37,5 ml

Pfizer Hellas A.E, . 243, . , 154 51 .T.: 210 67 85 800. http://www.pfizer.gr

22,5 ml ,

Pfizer Hellas A.E



- . - 11 , 2.000 , ( ) 6 - - . -, (< 3) - - . 6 . - - - . - . : , - - , placebo - - . - - - . , . - -, - .

Manheimer E et al.Meta analysis : Acupuncture forosteoarthritis of the Knee. Ann InternMed 2007 Jul 19; 146: 868 77.

- - . , 7 - , - 6 12 . 259 6 12 1/3 . -, , . ( - ), 3 - - 4 , - -, 6 ( 0.7 0 10) 12 . - 12 6 - (, ), - - . - - 0.7 0.6 ( - 0 10) 6 - 12 . -,

- - .



- ( 1,1 6 12) (-1.5 - 6 , -0.8 - 12 ). : - - . - , . Penkel LHM et al.Physiotherapist directed exercise,advice, or both for subacute low backpain : A randomized trial. Ann InternMed 2007 Jun 5; 146:787 96.

-, , - - . (aP2) - , . - aP2 , - - . - 50%, , - . - , - , . - - , - ,

-, . : - - , -, - . Furuhashi M et al.Treatment of diabetes and atherosclerosisby inhibiting fatty acid binding proteinaP2. Nature 2007 Jun 21; 447: 959 65.

AIDS - HIV, - - , . - CD4 - - . 1835 ( - ) , , CD4 204 /mm3 5 -, CD4 497 /mm3, 200 /mm3, 676 /mm3 - 201-350 /mm3 794 /mm3 > 350 /mm3. - CD4, - . , C CD4, - . : -

-, , CD4 - .



50-75 % HIV - , . , : , , - CD4 , - CD4. Mocroft A et al.Normalisation of CD4 counts in patientswith HIV-1 infection and maximumvirological suppression who are takingcombination antiretroviral therapy: Anobservational cohort study. Lancet2007 Aug 4; 370: 407-13.

: ; - , - - ( ) - . , , . - - - . 42 - , 3001 - 4 : -, , -. (792 ) - . 4 (311 ), - , -. -

, . : - , - . - - . - , - - . Palfreyman S et al.Dressing for venous leg ulcers: Systematicreview and meta-analysis. BMJ 2007Aug 4; 335: 244.

- - . - , - - . (- ) - , -. 30% -, -. 4 , - - , - . , - -. , , - , -, - -

- - , - - .


Boehringer Ingelheim E A.E. A: E 2, 167 77 E, T.: 210 89 06 300, : 15-17 & 6, 57001, , . 2310 424618, . : 210 89 06 326.

Lonarid N

...

.

..

D

C000

468

LON

ARID

N 0

4/09

1. LONARID N2. & : Paracetamol 400 mg

Codeine phosphate hemihydrate 10 mgCaffeine 50 mg

: Paracetamol 400 mgCodeine phosphate hemihydrate 20 mg

Caffeine 50 mg3. . . 4. 4.1. . E , . 4.2. . , , 4g, 240mg. 2,5 g. : 6 12 250 500 mg 6 . 6 12 2 3mg/kg . .4.3. . . . A , , , , ,, , , . , , 6 . 4.4. & . , , , , , , , , , . , . . 4.5. . , . . . , , , . . . 4.6. . : . : 4.7. . . 4.8. . , , , . , , . , , . ,, , , , , , , , , . . . , , , . . . 4.9. . .

, , , , , , ,, , . ,

. . . . , , , , , , , . , , , , , , , . -Acetyl-p-Benzoquinoneimine(NABQI), . , NABQI . , , . . , , . . 10g . , 25g. . 300 g/ml, 4 . 150g/ml . RUMACK MAHEW. . . . , 15 . 140 mg/kg .. 70 mg/kg 4, 17 .

. 150 mg/kg .. 20 % 200 .. 5% 15 . 50 mg/kg B.. 500 .. 4 100mg/kg B.. 1 L 16 . . 0.4 2 mg 5 . 10 mg. , 0.1 0.2 mg. 10 g/kg B.. , 100 g/kg .. 5. . 5.1 . , . . . , . - . . 5.2. . 10 60 . . . . 1 3 . . . . , , . . 3 4 . 10 . , , . . 5.3. . 6. . 6.1. : Silicon dioxide colloidal, sodium carboxymethylcellulose, cellulose microcrystalline,starch maize dried, ethylcellulose N 14, magnesium stearate.: soya lecithin, hard fat6.2. . 6.3. . : 60 . : 60 6.4. . : .: 6.5. . : 2 blister 10.: 6 6.6. /6.7. . Boehringer Ingelheim , 2, 167 77 , .: 210 8906111 7. : 8501-6/2/20078. : 19/3/1986 9. () : 10/1998

( S P C )

B :

A: N T OBAPE

N

24 2820161284g/mLmo/L

530

50

100

500

10001700

200030004000

RUMACK MATTHEW

10

50

100

500

400

300200150



. - - , . : -, - -. - - -. - . , , - - - , - . Aaltonen S et al.Prevention of sports injuries: Systematicreview of randomized controlled trials.Arch Intern Med 2007 Aug 13/ 27; 167:1585-92.

- - , . - , - . - 16 - , - -. , , , , ( 30kg/ m2) - , -

, - , ,, , -. - - 7 . - - . - ( 25 < 30) - , (- ) . : -. , - , - . , - - . Waller DK et al.Prepregnacy obesity as a risk factorfor structural birth defects. Arch PediatrAdolesc Med 2007 Aug; 161: 745-50.

; (MS) ( - ), - . - - - . -- (CRYAB), - MS . CRYAB, -

- MS - CRYAB - .


NARINI HELLAS A.E.

A. 7, 104 45 , .: 210 8316111-3, Fax: 210 8317343, e-mail: [email protected]

BRIVIR 5-fluorouracil 5-fluorouracil (.. capecitabine, floxuridine tegafur) 5-fluoropyrimidines .. flucytosine - 4 5-fluoropyrimidine. , - DPD 5-fluoropyrimidine BRIVIR.

125mg

4.3. : BRIVIR . : BRIVIR , 5-fluoro-uracil (5-FU), , 5-fluorouracil (.. capecitabine, floxuridine, tegafur) 5-fluoropyrimidines ( . 4.4. 4.5). - : BRIVIR .. , flucytosine . : BRIVIR . : BRIVIR ( . 4.6.). 4.8. : To brivudin 3900 . (2,1%). . brivudin . .

Menarini Hellas.

(1-10%) (0,1-1%) , , , , , , , , , , , , , , (, , ) ,



, - .

CRYAB - , - . - , - - . - CRYAB, . - - MS CRYAB . : , , CRYAB . , CRYAB - - , - MS. - . Ousman SS et al.Protective and therapeutic role for B-crystalline in autoimmune demyelination.Nature 2007 Jul 26; 448: 474-9.

Parkinson - , Parkinson . Parkinson (PD), - - - , Lewy -

- . - , - - PD. 2 (SIRT2). , - RNA, SIRT2 - -, - , - Parkinson. SIRT2 -, 2 -, - Parkinson . : - PD. - PD, SIRT2, - - -. Quteiro TF et al. Sirtuin2 inhibitors rescue -synuclein-mediatedtoxicity in models of Parkinsons disease.Science 2007 Jul 27; 317: 516-9.

; FDA - (RU-486) - , 2000, - , -, . - -

- PD.



, - ; , - , , 1999 2004. 2710 - 9104 . - , - , - - , , - . : - , . - - -, . : Virk J et al. Medicalabortion and the risk of subsequentadverse pregnancy outcomes. N EnglJ Med 2007 Aug 16; 357: 648-53.

- - , - . - , - -

. - , - 1834 - , , , - - . 3 - - - . , - - ( ). 40% - , - - 36%, - 70%, -. - -. : - - - - , . ,

- -.



. Walker S et al. Seasonalallergic rhinitis is associated with adetrimental effect on examinationperformance in United Kingdom teenagers:Case-control study. J Allergy ClinImmunol 2007 Aug; 120: 381-7.

- -. - - 14.187 - (3-18 ) - 3 1999 2006. - , . 507 (3,6%) - -, 3 -. , 131 (26% ) - (80 ) (51 ), , . - - 2, 10 . - - , - , . : - , , - ,

., . Hansen ML et al.Underdiagnosis of hypertension inchildren and adolescents. JAMA 2007Aug 22; 298: 874-9.

, - , - - . - , , 1009 , - 6 . - 131 . - 2 : ( - , - , - , ) - , ( ,, ). 5 -, 324 223 . , ., , - - , ,

- - 2, 10 - .


*&) (/)*&+7,,"-& ,( +(/2% 7,"-). ')1*$& !3( (/)*&+7,,"-. ,( +(/2% 7,"-). ')1*$. /(0)"6() # 45,.-.8'0)*%

9)&2:-;(0$+:-;0.?%-2.5&/(737-3($2(12:-(2&)0($&

!+,3-.#17&'%+ 5/#6"*21)3-!4(0*$,.



. - , . : -, - - -. . Meyerhardt JA et al.Association of dietary patterns withcancer recurrence and survival in patientswith stage III colon cancer. JAMA 2007Aug 15; 298: 754-64.

- , -. 2 , . - , 2.000 ( - 42 kg/ m2) - - - , 18 . - - (68%), (19 %) (13 %). 11 , 5% 6,3 % . - -, -

- . - 90 0,25 %. Utah, 8.000 ( 45 kg/ m2) - . 7 , 2,7 % 4,1 % - . - , 40%. 0,5 %. : - , - . - , - , - - -. - , - . Sjstrm L et al. Effectsof bariatric surgery on mortality inSwedish obese subjects. N Engl J Med2007 Aug 23; 357: 741-52.

- - (), - - - (, ).

- -, - - .


SEP/

2008

/MAG

/AD

/2

1. Walker A et al Mg citrate found more bioavailable than other Mg preparations in a randomised, double blind study, Magnesium Research, Vol 16, Number 3, 183-91 (2003)

!"# !$"%&'("%

!"!

#$%%

#")(!

! #"*("+"%%+%'

+%)(!

#""%,"+%' -+%'

)(!

!#&'#(%)

*!)$(.+*/(* "%0-%1 %"%

"*#



, - - - placebo, 60 - 2 . , 378 - , - - , . 3 , , - (37% 51%). - - -, - 10 - - (16 % 24%). : - - --, - , - - 12, . 2 - . Kappos L et al. Effectof early versus delayed interferon beta-1b treatment on disability after a firstclinical event suggestive of multiple

sclerosis: A 3-year follow-up analysisof the BENEFIT study. Lancet 2007Aug 4; 370: 389-97.

- , - . , - - 400 9 , - . , - 36 49 ( 42 ). , , -, - , - 80%. 60% -, - - . -, - ( [FSH]), - FSH , - -. - , . : -. - , - -,

- -, - .



. , 20% , - - . , - - - , . Freeman EW et al.Symptoms associated with menopausaltransition and reproductive hormonesin midlife women. Obstet Gynecol2007 Aug; 110: 230-40.

( -, ) - - . - , 11.093 65 . - . - ( 65-69 ) (90 ), - - : ( 3% 32%), - ( 6% 22%), ( 9% 27%), ( 1% 12%), ( 10% 18%), - ( 5 % 23 %) ( 19% 52%). 3 - - ( 3% 31%). - ( , - ),

- - - . : - - . , - - . Cigolle CT et al. Geriatricconditions and disability: The Healthand Retirement Study. Ann Intern Med2007 Aug 7l; 147: 156-64.

D- , - (DVT) -. - D- - - (SimpliRED), 149 DVT 5 - . - - 3 . DVT 13 ( 12 2 ). D-- -. 67 . 13 DVT, D- ( 100%). -, 81 DVT( 100%)., 138 DVT 54 -

- .



( 60%). 3 . : DVT . SimpliRED . - D-, , D- DVT . Chan W-S et al. A redblood cell agglutination D-dimmer testto exclude deep venous thrombosisin pregnancy. Ann intern Med 2007Aug 7; 147: 165-70.

, - - -. (PVS) , , . - (minimallyconscious state, MCS), - . PVS - MCS. - - . MCS - - -. , 38 MCS 6 . -

48 , 6 -, - - ., - 6 , - - - , . - , - . : - PVS, - . - . Schiff ND et al. Behaviouralimprovements with thalamic stimulationafter severe traumatic brain injury.Nature 2007 Aug 2; 448: 600-3.

- , 1 600 -, -. 70% , . - , . - 24 ( 7-17 ) - - - ,

- - - -.



- . , , - . - - , . : - - - - . - - -, - - . Nopoulos P et al.Abnormal brain structure in childrenwith isolated clefts of the lip or palate.Arch Pediatr Adolesc Med 2007 Aug;161: 753-8.

; - , in situ(DCIS), - MRI DCIS , - . - MRI DCIS ; , -

MRI , 7319 - - - - . (BI-RADS 4 5) - - . 168 DCIS, MRI - (92% 56%). - DCIS MRI DCIS - -. MRI - , , , - MRI . 55% 59% MRI. : MRI -, , -. , MRI - , - - . - , MRI - . , , - MRI . : Kuhl CK et al. MRI fordiagnosis of pure ductal carcinoma insitu: A prospective observational study.Lancet 2007 Aug 11; 370: 485-92.

- -, .


BB ::

A: N T OBAPE

N[ ]

OORROOCCIILL LLIIDDOO OORROOCCIILL lliiddoo(Benzoxonium chloride+ lidocaine hydrochloride) 11.. Orocil lido 22.. && . :benzoxonium chloride 1mg, lidocaine hydrochloride 1 mg . 1ml : benzoxonium chloride 2mg, lidocainehydrochloride 1,5 mg . 1ml : benzoxoniumchloride 0,5mg, lidocaine hydrochloride 0,5 mg 33.. HHHH , , 44.. 44..11.. . , ( ), , , . 44..22.. 2 . 2-3 , 1 10 . : . :: 3 - 6 . 4 . , . 0,5ml 1 mg benzoxonium chloride 0,75 mg lidocainehydrochloride. :: 30-60 15-20ml(1 ) ( ).

, , . . : Orocil lido 4 , . 6 . 2 3 . 10-15ml (1 ) . 44..33.. , . 4 . 44..44.. Orocil lido , . Orocil lido 2 , . . , . Orocil lido . , . 44..55.. . 44..66.. , . . , Orocil lido , 3 .

Orocil lido , . 44..77.. . 44..88.. , . . 44..99.. o , . . , . , 55.. ATC R02AA 55..11.. , Gram- Gram- . . , . , . . , , . Orocil lido . 55..22.. , , . ( 1% 24) . , 95%

. . . . 35% . . 66.. 66..11.. :: Sorbitol 1g, sodium saccharin,microcrystalline cellulose, macrogol 6000, Citric acid monohydrate, starchmaize, sodium chloride, magnesium stearate, orange flavor. :: Ethanol 96% (v/v), glycerol, peppermint oil, menthol, hydrochloricacid, purified water. Ethanol 96% (v/v), glycerol, sodiumhydroxide, citric acid monohydrate, peppermint oil, menthol, purified water. :: . :: (x24): 4,78e. (FL 30ml):5,68e. (FL 200ml): 6,18e. Novartis(Hellas) ... : 1. Novartis Consumer Health SA Data on file April 9, 2003 Expert report onthe Clinical Documentation.2. Catterall W, Mackie K (2001). Local anesthetics. The pharmacological basisof therapeutics. 10th ed. Goodman & Gillmans Mc Grow Hill.

OROCIL lido , . 4 . , . .

BBAARRAACCLLUUDDEE 11.. Baraclude 0,5 mg 1 mg 22.. 0,5 mg 1 mg entecavir ( ). : 0,5 mg 120,5mg 1 mg 241 mg . , . 6.1. 44.. 44..33.. . 44..44.. : ( 4.2). , . , . : ALT . , ALT HBV DNA ( 4.8). entecavir 4-5 . , ALT , . , ' . . HBV DNA, -. , , . , entecavir, 23-24 , HBeAg ( 4.8). 6 . , . - : - . 45 Child-Pugh 7 entecavir. , , , 6 . . : ( ), , , . entecavir , . , / . , , , . , , /,

. ( ) , . . , ALT . : HBV , entecavir (ETVr). , ETVr rtT184, rtS202 rtM250 . HBV entecavir . entecavir 1, 2, 3, 4 5 6%, 15%, 36%,47% 51% . . , 24 entecavir, ( 4.5 5.1). : ente-cavir . entecavir tacrolimus ( 5.2). C D: entecavir C D. (HIV)/HBV : ente-cavir HIV/HBV, HIV. HIV, entecavir HIV (HAART) ( 5.1). , entecavir HIV/HBV, HAART. entecavir HIV . HIV/HBV : entecavir 68 HIV/HBV, HAART ( 5.1). entecavir HBeAg- HIV. HIV CD4 (< 200/mm3). : entecavir HBV ' . : 120,5 mg 0,5 mg 241 mg 1 mg . , Lapp - . Baraclude .44..88 1.720 -

entecavir 0,5 mg/ (n = 679), entecavir 1mg/ (n = 183), (n = 858) 107. entecavir , , . entecavir (9%), (6%), (4%) (3%). entecavir . (1/10), (1/100, < 1/10). , .

(HBeAg ): ente-cavir 0,5 mg 53.

: , , :

: , ,,:

: :

: :

: 2% ALT > 10 (ULN) > 2 , 5% ALT > 3 , < 1% ALT > 2 > 2 ULN > 2 . < 2,5 g/dl 3 2%, > 3 11% < 50.000/mm3 < 1%. 48 : entecavir 96 .

: ente-cavir 1 mg 69.

: : : ,

: , ,, :

: :

: :

: 2% ALT > 10 ULN > 2 , 4% ALT > 3 , < 1% ALT > 2 > 2 ULN > 2 . > 3 2% , > 3 18% < 50.000/mm3 < 1%. 48 : entecavir 96 . : , ALT

> 10 ULN > 2 2% entecavir 4% . , ALT > 10 ULN > 2 2% entecavir 11% . entecavir, ALT, 4-5 , , 2 log10/ml ALT. . : , ente-cavir ( 4.4). , 6% entecavir 10% ALT (> 10 ULN > 2 [ ]) . entecavir, , ALT 23-24 86% (24/28) ALT HBeAg . , , 11% entecavir ALT . entecavir . , ALT . HIV: entecavir HIV/HBV HAART( - highly activeantiretroviral therapy) HBV ( 4.4). /: entecavir ( 25% ) (5% > 65 ). : . 45 Child-Pugh 7 entecavir. : , entecavir.

: :

77.. ,, BRISTOL-MYERS SQUIBBPHARMA EEIG Uxbridge Business Park Sanderson Road UxbridgeUB8 1DH ()HYPERLINK http://www.emea.europa.eu/Baraclude () 0,5 mg, 30 : 386,52, 444,28 653,76. Baraclude () 1 mg, 30 420,19, 482,98 710,71. 100%.

~~~~


EENNEEAASS:: 10 mg 20 mg : . . , . , : . : ENEAS . , ENEAS . , , ENEAS . : ENEAS ( 10 ml/ min) . : ENEAS , .:: ENEAS : , . / . , , , , . . ( 10 ml/min) . . : , , , , , , . , , . . , . 12 24 . /:/, . , . , , , , . ENEAS , . . ENEAS ( 1000/mm3). : , , . -. ( 30 ml/min, _3 mg/ml), , . , . , , . ENEAS . : . ( 1 g/), ENEAS - . : , ENEAS , , . ENEAS . . , . / : , . , . : , / . , . , .: , ENEAS - - , , , , , . . ,

, . , , . . , . , , , . ENEAS, . : , . , . : . . : , -. , . : ENEAS (, 2- ) (.. "AN 69") ,, . , . ENEAS . LDL/ : . () (.. ) (.. , , ), . LDL () , . / , . , , . : in vitro , , . , in vitro , , . : , , , ' , . , Lapp . ENEAS , - - . , : : : . , (.. ) , . . , , . : , , . , . : , . / , . , . : , . : . , . : . : . , ,, , : . : . : , , . : .

. , , , . : . : . , . P450 3A4, . , (.. , , ) . , (.. ) . -: - . - , . : ENEAS . . , , , , . , , , . , , . . , . , , ENEAS . . , . : ENEAS . , . :: ENEAS , . , / . . :: ENEAS . ( 1-10%): , , . (0,1-1%) , , , , , . (

XXEERRIISSTTAARR 11.. XERISTAR 30 mg, 60 mg - 22.. - 30 mg 60 mg ( ) -. : 8,6 mg 17,2 mg . , 6.1. 33.. .A , 30 mg - , 9543, - , 60 mg - 9542. 44.. 44..11 . . - . 44..22 - EE 60 mg , . 60 mg , 120 mg , , . , , , - . , - 2-4 . , , . :: - - 30 mg . - 60 mg, - . 60 mg ( - ). 120 mg - - , . 60 mg, - 90 mg 120 mg. . , - , -. :: 60 mg , . 60 mg , 120 mg , , , -. - ( 5.2). , - , 60 mg , . - 2 . , - . ( 3 ) ( 5.1). :: . - . -, , - , XERISTAR 120 mg - ( 4.4 5.2). ( 4.4). A XERISTAR ( 4.3 5.2). - - ( 30 80 ml/min). XERISTAR ( 10 ), , (- 4.8). - . . - - . - XERISTAR . , -- , . 44..55 :: : , , . , - , XERISTAR , - ( , -, , , -). (Is): , -, - (Is) 14 - I. - 5 - XERISTAR I ( 4.3). , Is, , -. , XERISTAR , Is ( 4.4). : , - (SSRIs . , -) . XERISTAR SSRIs, - , St Johns wort(Hypericum perforatum), , , , . - CYP1A2: , CYP1A2, - (60 mg ). CYP2D6: CYP2D6.

60 mg - , CYP2D6, -AUC . - (40 mg ) -AUC (2 mg ) 71%, 5- . XERISTAR , - CYP2D6, (, - [TCAs] , ) ( -, ). - : in vitro , - CYP3A. in vivo - . - : -, . , INR - . - , , , INR R- S-. - 2-: - -, 40 mg -. CYP1A2: CYP1A2 - , - CYP1A2 . (100 mg -), CYP1A2, 77% 6- AUC0-t. , XERISTAR CYP1A2, - ( 4.3). CYP1A2: - , , 50%, - -. 44..66 : . - (AUC) ( 5.3). - . , - - . XERISTAR ( ) . , , . : , 6 . - , mg/kg, 0,14 % ( 5.2). , XERISTAR . 44..77 -- . XERISTAR . . 44..88 :: - 1 , (placebo), , - ( 6.828 , 4.199 - 2.629 ). - XERISTAR , , , . , - , - . 1: -: ( 1/10), ( 1/100 < 1/10), ( 1/1.000 < 1/100), ( 1/10.000 < 1/1.000), (< 1/10.000), ( ). - . - : - : : : : :: : ( - ). :, , SIADH. : : , , , , , - . : , , -, . : , , - 4 : 5, 5. : : - (14,3 %), (10,7 %), (10,2 %). : T, -. : , , -, , , , , . :1. : - , , , - . O : : . : M, . . : :1. :, . : : . : T-, . -: : . : , - , O 2, 2, : , . - , : : -. : , . : : N (24,3 %), - (12,8 %). :, , , , -. :, E, . : - , , , : . : : (ALT, AST, ), H 3, . : , . : : , . : , , , , , . - : , Stevens-Johnson. :: , , . : . :. : : , , , N, , . : . - : : . : , , , . : - -: : , . : --, , , , , , . : . : : . : , .: . 1 .2 . 3 4.4. 4- . 5 -

( 4.4). (- ) ., ( ), ( ), , , / , , -, , , . , SSRIs SNRIs, , / . , , - ( 4.2 4.4). , , 12 , , . HbA1c - , . - , 52 , - HbA1c , , - 0.3% . -, . To QT- -, , (placebo). - QT, PR, QRS, QTcB, (placebo). 44..99 :: - ( ) - , 5.400 mg. - , , 1.000 mg. ( - ) , , , , , . , , ( / - ). -. , - . -, -. . , , . 55.. 55..11 : . ATC: N06AX21. - (5-) - (). , , , . - - - . - - , . . E - : XERISTAR -, 3.158 (1.285 - ), DSM-IV -. XERISTAR, 60 mg , -, , (placebo), , , - . , XERISTAR -, 60 mg 120 mg, - -, , - (placebo), , , . XERISTAR - (placebo), - Hamilton, (HAM-D), 17- ( ). - , , XERISTAR (placebo). (HAM-D>25 ). , - XERISTAR60 mg , 12-, XERISTAR60 mg (placebo), 6-. XERISTAR 60 mg - (placebo) (p= 0,004), - , , . , 6- -, 17% 29% - (placebo), . XERISTAR60 mg (65 ) HAMD17 - (placebo). XERISTAR 60 mg -. , (120 mg ) . - XERISTAR - , , -, , - . XERISTAR (placebo), - Hamilton, - (HAM-), Sheehan (SDS). , , XERISTAR (placebo). XERISTAR - Hamilton, - (HAM-). - XERISTAR, - 6 , XERISTAR (placebo) 6 . XERISTAR A 60 mg 120 mg (placebo) (p< 0,001) -, . , 6- 14 % XERISTAR 42% (placebo). XERISTAR 2 , 12 , -, - (placebo), (22 88 ) - 6 . -. 24- , 11- Likert. XERISTAR 60mg 60 mg -

, . . . 30 % 65% 40 % - . 50 % , 50 % 26 %, . - (50 % ) - . , - 47 % 27 % - . - 60 % 30 % . - 30 % 60 , - . - , - 8- XERISTAR 60 mg , - 6 24 Brief Pain Inventory (PI). 55..22 --:: . - (CYP1A2 CYP2D6 ). - . - ( 50-60 %) , , CYP2D6. : Cmax 6 - . - 32 % 80 % ( 50 %). - 6 10 ( 11 %). .: 96 % . -1 . -. : . CYP2D6 CYP1A2 - , , 4- - , 5- 6- . in vitro , - . - CYP2D6, . - , . : 8 17 ( 12 ). 22 L/hr 46 L/hr ( 36 L/hr). - - 33 261 L/hr ( 101 L/hr). : : - ( 50 % ). - , , - . : ( 65 ) ( AUC 25 % 25 % - ), . - ( 4.2 4.4) - : (ESRD) , Cmax AUC . . : ( Child Pugh) -. - 79 % , - 2,3 -AUC 3,7 . - - . -: 6 12- . . 7 g/ 40 mg . -. 55..33 . - . . 2 - - (144 mg/kg/), - . - . - (45 mg/kg/) - , , , , (AUC). , (AUC). , - . / - - (AUC). 66.. -- 66..11 :, -, , , T, (E171), , : 30mg: , , (171), (132), -, : (172), (172), -, 66..22 .66..33 3 . 66..44 . 30oC.66..55 -blister - (PVC), (PE) (PCTFE) . XERISTAR 30 mg - 28 . XERISTAR 60 mg - 28 . 66..66 -- . 77.. Boehringer Ingelheim International GmbH, Binger Str. 173 D-55216 Ingelheimam Rhein, . 88.. (()) EU/1/04/297/001,EU/1/04/297/006 99.. // : 17 2004, - : 21/08/2009 1100.. -- () http://www.emea.europa.eu. XXeerriissttaarr 3300mmgg:: NN..TT..:15,71 XX..TT..: 18,06 ....:: 26,58, XXeerriissttaarr 6600mmgg:: NN..TT..: 25,62 XX..TT..:29,45....:: 43,34. .Boehringer Ingelheim .. 2, .. 167 77, -, .: 210 8906 300, .: : 210 8906326. : 15-17 6, .. 57001, .: 2310 424 663.


MMAAGGNNEESSIIUUMM--SSAANNDDOOZZ -- ((SSmmPPCC)) 11.. Magnesium-Sandoz 22.. 1 : 1193.57mg trimagnesium dicitrate 667.56 mg magnesiumaspartate dihydrate, 243mg (10 mmol ) - 6.1 33.. -- , 44.. -- 44..11.. , -. , ( , , .. , - ). 44..22.. : (1-2) , 243 486 mg (10-20 mmol -) . 6 9 ( 20 29 ): (0,5) 121.5 mg (5 mmol ) . - 10 12 ( 30 43 ): (1) 243 mg (10 mmol) . N : 1 - 257 mg . - : . - . - , - 4 . - . 44..33.. Magnesium-Sandoz - : - : - (PKU), Magnesium-Sandoz

, - . 44..44.. -- : - ( ) , - - AV () . - , . -, - . Magnesium-Sandoz - . , () , - ( ). 44..55.. -- -- - , , -, , - -. - . - - , - -. - . - , - , -,

- . 44..66.. -- - - / . Magnesium-Sandoz . 44..77.. -- - 44..88.. , - . - , - . - -. , - . . 44..99.. , - - . - , - , , , ( AV (- ) ), . . - - . -- 55..11.. : ATC: A12CC 30. , - - . 300 - , ,

ATP. - - . 55..22.. - . - 30% 40% 70% . - , , - . 2-3 . 0,8 1,1 mmol/l. 40% - , - . , . 95% 100%, - . - ( , , ) - ( , , - ).55..33.. -- - , . - -. 66.. , -, , , - , , -, , , ,. . ..:10,42e,..: 15,33e. . :210-7793777.

EEFFIIEENNTT ((pprraassuuggrreell)) E 5 mg & 10 mg. EE Efient - (), - - (. -, ST[UA/NSTEMI] - - ST [STEMI]) - (PCI). Efient - 60 mg 10 mg . Efient - () (75 mg 325 mg). - 75 Efient 75 . - / , - - 75 , 60 mg, - 5 mg. < 60 kg Efient - 60 mg - 5 mg . 10mg . - . Efient . - . AA . . - - (). (ChildPugh C). EE -- -- - (PCI) Efient - . ,

Efient - -, - , . : ) 75, ) (.. , - , - - ), ) < 60 kg & ) - - , - -, , - () . - - - , Efient - 7 - . - (P) Efient - - - . , Lapp - Efient. AA -- :: H Efient . - - , ( ) - . -- (()):: . , ( - COX-2) Efient - . Efient

- P450 -) P450. Efient - - , , - pH, - 2 . - , 3 - Efient - , - GP IIb/IIa ( - GP IIb/IIa ) - . -- -- EEffiieenntt:: - (): Efient - (). , -, - - . : - (100 U/kg) - - . -, - . , -. : H (80mg ) - . pH: H - AUC max - , -

Cmax. CYP3A: CYP3A - ( ), - V, -, , ,, , - - - . - P450: CYP3A , - P450 - -. ffiieenntt :: : - . - CYP2C9: CYP2C9, - S-. , Efient - . - CYP2B6: - CYP2B6. - - - CYP2B6 - (.. -, ). A - - (PCI) - (TRITON). - - 7.2% 6.3% -. -- - -. ( 1/100 < 1/10), ( 1/1000 < 1/100), ( 1/10.000 < 1/1.000).: - :. : -. -

, : . - : . - - : , . - : . - -: , . , - - : . : : . - , - : -. : -, . -, . , - : -. : , - : . YY-- Efient - . - . , - , / - -. AAEEII KKYYKKOOOOPPIIAAli Lilly Nederland B.V., Grootslag 1-5, NL-3991 RA Houten, .AAPPIIMMII 5MG:EU/1/08/503/001-007, 10MG:EU/1/08/503/008-014. HHMMEEPPOOMMHHNNIIAAPPTTHH // AAEEIIAA 25/02/2009 HHMMEEPPOOMMHHNNIIAAAANNAAEEPPHHHH TTOOYY KKEEIIMMEENNOOYY25/02/2009 :: Efient fc tabs28x5mg : e53.98, T: e46.96,T: e79.43, Efient 28x10mg fc tabs: e53.98, T: e46.96, T:e79.43 .. -- --


PPAANNTTIIUUMM 11.. -- Pantium40 mg 22.. -- 40 mg ( pantoprazole sodiumsesquihydrate). : - 36 mg . 6.1. 33.. -, -, . 44.. 44..11 -- - . - - - - - Helicobacter pylori - - Zollinger-Ellison . 44..22 Pantium 40 mg -. 40 mg (1 Pantium40 mg). . - , -. 40 mg - (1 Pantium 40 mg). -. , - -. Helicobacter pylori (H. pylori) 40 mg 2 (1 - Pantium 40 mg 2 ) - -: ) 1 g + 500 mg ) 250?500 mg + 400?500 mg ) 1 g + - 400?500 mg . -. - 7 14. - (.. ) - . Zollinger-Ellison . - Zollinger-Ellison , 80 mg (2 Pantium 40 mg). - , . 80 mg , - . 160 mg - . Zollinger-Ellison - . 40 mg H. pylori, - (2 ? 40 mg/) -. - 40 mg . H. pylori ( 4.3). 40 mg ( 4.3 4.4). - . , - . - H. pylori -. . . 44..33 . , ( 4.5). - . - , 40 mg . , H.pylori

44..44 -- . 40 mg - . -, - , . ( 4.2 4.3). 40 mg - . , . - - - - . - Salmonella Campylobacter. - Zollinger-Ellison-Syndrome - - , , - 12 () - . , - 12 - . , - - . 4 . . Pantium . - , . 44..55 -- - , - pH (.. , ,

). . - -. - P450. - , . , - , , , , -, , , , , -, , , , , . - phenprocoumon , R . , / R . . 44..66 . - . - , ( 5.3). . -- - . , . 44..77 - ( 4.8). - . 44..99 . 240mg 2 -

. , . - - . 55.. 55..11 -- : - ATC: A02BC02 - - . - - , +, +-ATP, - . . . - 2 -, - , . . - - , - . (, , ). . 55..22 -: H . , 2.0?2.5 1?1.5 g/ml . 0.15 l/kg 0.1 l/h/kg. 1 . - . , ( ). . 10 80 mg, ,

. 98%. . ( 80%) , - . , . ( 1.5) -. . - 77%. - (AUC), - . - . - / : ( ). , . . (2-3 ), . - 40 mg - . ( Child), 3 6 (AUC) 3-5, - 1.3 . - (AUC) - (Cmax) - , . 55..33 , - , - . - . , - . - , - - - . , - ( ) . 2 -, (200 mg/kg) - . - . - , - . , - DNA, -. - . -. . 66.. -- 66..11 : , ( ), , (420), : , (25), (171), (172), , - , , 80, 6000, . 66..22 -- 66..33 3 . 66..44 -- Blister: . : . -- blister (OPA/Aluminium/PVC film aluminiumfoil) . 7, 14,15, 28, 30, 56, 60, 84, 100, 100 x 1, 112 140 - . HDPE silica gel - PP. : 250 . 66..66 - 77.. WIN MEDICA , 41, 115 28 88.. 8050/13-4-2009 99.. -- 28-2-2008 1100.. -- 28-2-2008 :: Pantium 40mg/tab BTx28 ( blisters) 34,99

44..88 :: 1/100 < 1/10 1/1.000 < 1/100 1/10.000 < 1/1.000 < 1/10.000,

, -

, (

) , ,

, -,

. , -

Stevens-Johnson, , Lyell, .

. . , (-

- -), -,

ZZIITTHHRROOMMAAXX ZITHROMAX 2 g () -- :: ZITHROMAX2 g - - , : ( - , in vitro -): - Haemophilus influenzae, Moraxella catarrhalis,Haemophilus parainfluenzae Streptococcus pneumoniae.- Chlamydia pneumoniae,Haemophilus influenzae, Haemophilus parainfluenzae, Moraxellacatarrhalis, Mycoplasma pneumoniae Streptococcuspneumoniae.( ). :O Haemophilus influenzae, Moraxella catarrhalis, Streptococcuspneumoniae. Streptococcus pyogenes. , - -, . - Streptococcus pyogenes . - , - . : - , -

- - : , - , , ( - ). -- :: ( 1 2 )- 5.2, . : - 2.0 g . - 5 . : 12 . : - - - ( 5.2, ). : - (GFR 10-80 ml/min). - - (GFR 1/100, 1/1,000, 1/10,000,

SSEEVVIIKKAARR ..OOllmmeessaarrttaann mmeeddooxxoommiill aammllooddiippiinnee (( aammllooddiipp--iinnee bbeessiillaattee)) ((2200 ++55))mmgg//TTaabb,, ((4400 ++ 55))mmgg//TTaabb,, ((4400 ++ 1100))mmgg//TTaabb:: . SEVIKAR olmesartan medoxomil amlodipine .:: , . . . . amlodipine SEVIKAR : , ( 4 ), . :: : / , , , , . SEVIKAR . --: -- (.. , ), , , , , , . : --. : SEVIKAR . SEVIKAR (

EENNBBRREELL11.. Enbrel 25 mg . 22.. 25 mgetanercept. etanercept p75 Fc - , DNA hamster. H etanercept -2 Fc IgG1. Fc , CH2 CH3, CH1 IgG1. H etanercept 934 150 kilodaltons. etanercept 375 . - etanercept 1,7 x 106 units/mg. 33.. . 44.. 44..11 -- Enbrel -- , ( ), . Enbrel ,, .. , Enbrel , , . 44 1177 , . Enbrel 4 . -- - . - ,, . 44..22 Enbrel - , . ((1188--6644)) 25 mg Enbrel 1 ml , . 25 mg . , 25mg -. (( 6655 )) . 18-64 . (( 44

AABBIILLIIFFYY.. ABILIFY 10 mg, ABILIFY 15 mg, ABILIFY 30 mg, ABILIFY 10 mg, - ABILIFY 15 mg, ABILIFY 1 mg/ml 11.. ABILIFY 1O mg: 10 mg -. : 62,18 mg .ABILIFY 15 mg: 15 mg . : 57 mg ABILIFY 30 mg: 30 mg .: 186,54 mg - ABILIFY 10 mg: 10 mg . : 2 mg (951) ABILIFY 15 mg: - 15 mg . : 3 mg (951) - ml ABILIFY 1 mg -. : 200 mg ml, 400 mg ml, 1,8 mg (28) ml, 0,2mg (216) ml - , . 6..11..33.. 10 mg: " 008" "1" . 15 mg: , " 009" 5" . 30 mg: , " 011" '30" . 10 mg: , "" "640" 10 . - 15 mg: , "" "641" 15 . :, 44.. 44..11 To ABILIFY . LIFY - ( 5.1).44..22 . -: ABILIFY 10 15 mg/-, ( 10 15 ml /) 15 mg/, , . To ABILIFY 10 30 mg/ ( - 10 30 ml /). - 15 mg . 30 mg. : ABILIFY 15 mg ( 15 ml /) - ( - 5.1). - . 30mg. - : , . , - , - . - , . . . - , - . , . ABILIFY ABILIFY ( 5.2). ABILIFY - ABILIFY - ABILIFY ( 5.2). - . : - 18 . : . -, . . , 30 mg - ( - 5.2). : - . : ABILIFY - 65 . , - - ( 4.4). : , ( 5.2). : - , - ( 4.5). - CYP34 CYP2D6 , -. CYP3A4 CYP2D6 , ( 4.5). CYP3A4 , . CYP3A4 , - ( 4.5). 44..33 - . 44..44 -- -, , . . - - -, ( 4.8). - . - : (- , - , ), , - (, -, - ) , - . : , - QT . -, - QT. (Tardive Dyskinesia): - , - - . ABILIFY,-

. - , . - (Neuroleptic Malignant Syndrome, NMS): NMS , . , - MS . MS , , - ( , -, ). -, - () . , -, NMS. - NMS, - NMS, , ABILIFY . : - , . -, - . - : -: (=938. : 82,4 , : 56 99 ) Alzheimer, - . 3,5% 1,7% . , - (.. , ) (.. ). -: , - (.. , ), - , (: 84 , : 78 88 ). , 1,3% - 0,6% . . , , , - . ABILIFY . -- : , - , , ABILIFY. - , . , - - ( -) - . - - ABILIFY , . - - ABILIFY, ( , -, ) - -. : - -, , , - . - ABILIFY, / -, , - . - ( - 5.1).: , - ABILIFY - . : , - lapp - - . POM : ABILIFY , - . : -. . - - ( ). . , - - . : , - , , ( - 4.8).44..55 - , . - , (-) - ( - 4.8). QT . ABILIFY: - , 2 , , . , CYP2D6 CYP3A4 CYPIA. , - . - , CYP2D6 () - AUC 107%, Cmax . AUC Cmax -, , 32% 47%. ABILIFY -, ABILIFY . - C2D6, , - ' . - , CYP3A4 (-) UC Cmax 63% 37%, . AUC Cmax -,

77% 43%, . CYP2D6, - CYP3A4 - CYP2D6. - CYP3A4 ABILIFY, - -. ABILIFY, ABILIFY . CY34, V, - ' . CYP2D6 34, ABILIFY - / CYP3A4(.. -) CYP2D6 ABILIFY, - . -, CYP3A4, Cmax AUC 68% 73%, , - (30 mg) . , - Cmax AUC - 69% 71% -, , . ABILIFY ABILIFY . CYP3A4 ( , ,, , , , (St. John's Wort)) - ' . CYP3A4, ABILIFY - . , - . ABILIFY : , - 10 30 mg , - CYP2D6 ( -/3-methoxymorphinan), 2C9 (), 2CI9 () 34 (). , -- CYP1A2, in vitro. , - . - , -. 44..66 . - ( 5.3). - . , . - , . . . 44..77 - . , -, - - . 44..88 - (1/100) , - (*): - -: (> 1/100, < 1/10), (> 1/1.000, < 1/100). : * - : , , -, , , , : : -, , , , : * : : , , : -* - ():- 52- , - (25,8%), , , - (57,3%). 26- , 19% 13,1% . 26-, 14,8% - 15,1% . - - 12 , 23,5% 53,3% . 12 , - 26,6% 17,6% . - 26 -, 18,2% 15,7% -. , 12,1% - 3,2% . 6,2% 3,0% - , - - , . CPK () 3,5% - 2,0% . : - -, , -, , , - ( 4.4). : - . ( ). : - , ,

, - : QT, , - , , , : , , - : , - (MS), - , : , -, - : -, , , , : , : , , , - - : , , - : , , , - : , , , : , , - : (.. ,), , - : (.. , , , , , ) - : , , (ALT), - (AST), (GGT), : : -, , , "" ( 4.4) 44..99 -- , - - - 1.260 mg . - , , ,, , . , - ( 195 mg) . - -, . , - , - . - . ' - . - , - . (50 g) -, Cmax 4i% AUC 51% , . , - , - . 66.. 66..11 10 mg: , , - , , -, (72) 15 mg: -, , , , , (172) 30 mg: , , - , , , - (72) 10 mg: , ,, , , , (951), . ( -), , , (172)- 15 mg: -, , ,- , . , (951), . (- ), , - , (172) : , , , , - (218), -, (216), , , -, . 66..22 -- .. 66..33 : 3 : 3 . : 6 6.4 : . : . 6.5 : 28 x 1 .- : 28 x . : PET , 150 ml . - 6.6 - . 77.. OtsukaPharmaceutical Europe Ltd. Hunton House Highbridge Business Park,Oxford Road Uxbridge Middlesex UB8 IHU 88..(()) 28x10 mg: EU/I/04/276/007 28 x15 mg: EU/I/04/276/012 28x30 mg: EU/I/04/276/0I7 28x10 mg: EU/I/04/276/025 28x15 mg: EU/I/04/276/028 1 mg/ml -150 ml: EU/l/04/276/034 99.. -- // : 4 2004 1100.. -- 03/2008 - () http://www.emea. europa.eu/. -: ABILIFY. - : Bristol-Myers Squibb .., 49-53 & - 2,152 35 , . : +30 2 10 60 74 300.- : Abilify Tabs bt 28x10mg: 4,73e,Abilify Tabs bt 28x 15mg:141,73e, Abilify Tabs bt 28x30mg: 245,52e, Abilify disp tabs bt 28 10mg: 155,51e,Abilify disp. tabs bt 28xI5mg: 161,79e Abilify OSlmg/ml-150 ml: 98,24e. : Abilify Tabs bt 28 10mg:83,80e, Abilify Tabs bt 28xI5mg:83,80e, Abilify Tabs bt28x30mg:145,16e.Abilify disp. tabs bt 28x10mg: 91,94e,Abilify disp.tabs bt 28x15mg: 95,66e.Abilify OS lmg/ml-150 ml:117.2le - : 100%.



- . -

, -, . - . . - , - : 18 - happy birthday to you, , . -- . , - ; - - - .

, ., - , . 10 2009 () . -, , , . , -

- - , 2007. - , - , - , 1. - . - , , - .

. -, - , . , 10 2009 , (enormous) 2 - - , - . - CNN: 3.

, - -, , : , -

. - , .

... (-) 0,1 %, -, . - ,, , , -

...


-, -. , , - .

- , - . - , , -

, - -. -. , -, , , . , , - , .

, - -, , , . - Eurosurveillance, - - 0,0004 0,06% 3 250 2 -. , -, . - , . - . . . -, - , - 3000. - -, - 162 4.

, - -

, - , , - 65 , 5. , - .

, , . - -. - , - 5000 35000, - . BritishMedical Journal concern bias, -6, , .

... , -, - , 1968 - - 11. , , . , -, -, ,




- . , , happening - - . , , .. , - .

... . , , . - Meryland , H1N1 -, - - 7.

- -, , - .

- -

, , - .

- . , .

1)"http://www.who.int/csr/disease/swineflu/notes/h1n1_safety_vaccines_20090805/en/index.html2)WHO. Pandemic preparedness. http://web.archive.org/web/20050207101237/http:/www.who.int/csr/disease/influenza/pandemic/en/3)"http://edition.cnn.com/2009/HEALTH/05/04/swine.flu.pandemic/index.html4) http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=192554)http://www.healthemergency.gov.au/internet/healthemergency/publishing.nsf/Content/2FBF38115CD98BB7CA25762A00121475/$File/090909.pdf 5) Simonsen L, Taylor RJ, Vibourd C etal. Mortality benefits of influenza vaccinein elderly people: an ongoing controversy.Lancet Infect Dis. 2007;7:658-66.6) Doshi P. How should we plan forpandemics? BMJ 2009, 339:b3471.7) Perez, D., Sorrell, E., Angel, M., etal. PLoS Currents (2009). Fitness ofPandemic H1N1 and Seasonal influenzaA viruses during Co-infection.

- - -, - -, ,

(11), , (), -, , . , - , , , . , . , , , . - , , 150 - . , . : . . : - . , , , 39.000 , -, .


medical_t_179

Documents